Last reviewed · How we verify
Optison
At a glance
| Generic name | Optison |
|---|---|
| Also known as | ultrasound contrast agent, Echocontrast agent, Perflutren Microspheres Injectable Suspension, USP, Perflutren Protein-Type A Microspheres Injectable Suspension, USP, perflutren protein-type A microspheres |
| Sponsor | Mayo Clinic |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Boxed warnings
- WARNING: SERIOUS CARDIOPULMONARY REACTIONS Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration. Most serious reactions occur within 30 minutes of administration [see Warnings and Precautions (5.1) ]. Assess all patients for the presence of any condition that precludes OPTISON administration [see Contraindications (4) ]. Always have resuscitation equipment and trained personnel readily available [se
Common side effects
- Headache
- Nausea and/or vomiting
- Warm sensation or flushing
- Dizziness
- Dysgeusia
- Chills or fever
- Flu-like symptoms
- Malaise/weakness/fatigue
- Chest pain
- Dyspnea
- Injection site discomfort
- Erythema
Serious adverse events
- Fatal cardiac or respiratory arrest
- Anaphylaxis
- Ventricular fibrillation
- Ventricular tachycardia
- Shock
- Syncope
- Loss of consciousness
- Convulsion
- Bronchospasm
- Angioedema
Key clinical trials
- Perflutren Protein-Type A Microspheres and Contrast-Enhanced Ultrasound in Improving Response to Radioembolization Therapy in Patients With Liver Cancer (PHASE2)
- Contrast-Enhanced Ultrasound for the Prediction of Bile Duct Cancer Response to Radioembolization Treatment (PHASE2)
- TULIP ReTrain Study (NA)
- Two and Three Dimensional Contrast-enhanced Ultrasound for Screening of Renal Cell Carcinoma Recurrence Following Cryoablation (PHASE2)
- Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Kidney Cancer Undergoing Cryosurgery (EARLY_PHASE1)
- Regadenoson Real Time Perfusion Imaging Trial-Optison (PHASE3)
- Detection of Coronary Stenosis With Intravenous Microbubbles (NA)
- Contrast-Enhanced Ultrasound and Shear Wave Elastography for the Treatment of Lymphedema (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |